Table 21-12.

Quality of Care by Race/Ethnicity and Sex in the GWTG-HF Program

Quality-of-Care Measure	White	Black	Hispanic	Men	Women
Postdischarge appointment (new for 2011)*	14.4	16.6	14.8	15.0	13.1
Complete set of discharge instructions†	93.3	94.2	91.5	93.9	93.0
Measure of LV function *	99.4	99.5	98.8	99.3	99.1
ACEI or ARB at discharge for patients with LVSD, no contraindications*	95.0	96.5	94.1	95.3	95.4
Smoking cessation counseling, current smokers†	99.1	99.3	97.8	99.1	99.1
Evidence-based specific β-blockers*	57.8	62.9	64.5	61.9	60.6
β-Blockers at discharge for patients with LVSD, no contraindications†	96.6	96.7	95.0	96.5	96.2
Hydralazine/nitrates at discharge for patients with LVSD, no contraindications	…	13.0	…	12.7‡	12.1‡
Anticoagulation for atrial fibrillation or atrial flutter, no contraindications	77.7	73.2	72.2	77.1	73.7
Composite quality-of-care measure	57.5	61.4	59.6	59.7	56.6
Composite quality-of-care measure (historical measures)	91.5	91.7	88.2	90.8	91.6

Values are percentages.

GWTG-HF indicates Get With The Guidelines–Heart Failure; LV, left ventricular; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; and LVSD, left ventricular systolic dysfunction.

^*Indicates the 5 key achievement measures targeted in GWTG-HF.

^†Indicates historical key achievement measures in GWTG-HF.

^‡For black patients only.